Jian Ge

Dr. Jian Ge


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2019 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
JHJiansong Huang
Jiansong Huang
XLXia Li
Xia Li
XSXiaofeng Shi
Xiaofeng Shi
MZMark Zhu
Mark Zhu
JWJinghan Wang
Jinghan Wang
JJJie Jin
Jie Jin
Integrins are a family of transmembrane glycoprotein signaling receptors that can transmit bioinformation bidirectionally across the plasma membrane. Integrin αIIbβ3 is expressed at a high level in platelets and their progenitors, where it plays a central role in platelet functions, hemostasis, and arterial thrombosis. Integrin αIIbβ3 also participates in cancer progression, such as tumor cell proliferation and metastasis. In resting platelets, integrin αIIbβ3 adopts an inactive conformation. Upon agonist stimulation, the transduction of inside-out signals leads integrin αIIbβ3 to switch from a low- to high-affinity state for fibrinogen and other ligands. Ligand binding causes integrin clustering and subsequently promotes outside-in signaling, which initiates and amplifies a range of cellular events to drive essential platelet functions such as spreading, aggregation, clot retraction, and thrombus consolidation. Regulation of the bidirectional signaling of integrin αIIbβ3 requires the involvement of numerous interacting proteins, which associate with the cytoplasmic tails of αIIbβ3 in particular. Integrin αIIbβ3 and its signaling pathways are considered promising targets for antithrombotic therapy. This review describes the bidirectional signal transduction of integrin αIIbβ3 in platelets, as well as the proteins responsible for its regulation and therapeutic agents that target integrin αIIbβ3 and its signaling pathways.

2 May 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
LYLichen Yang
Lichen Yang
MWMeng Wu
Meng Wu
JRJie Ren
Jie Ren
DYDu Yali
Du Yali
JGJian Ge
Jian Ge
LYLichen Yang
Lichen Yang
Our aim was to evaluate the cut-off value and efficiency of using reticulocyte hemoglobin content as a marker to diagnose iron deficiency anemia in Chinese adults. 140 adults who needed bone marrow aspiration for diagnosis at the hematology department of the Peking Union Medical College Hospital were enrolled according to the inclusive and exclusive criteria. Venous blood samples were collected to detect complete blood count, including hemoglobin, reticulocyte hemoglobin content, hematocrit, mean cellular volume, corpuscular hemoglobin concentration, hemoglobin content, free erythrocyte protoporphyrin; iron indexes of serum ferritin, serum transferrin receptor, and unsaturated iron-binding capacity; and inflammation markers of C-reactive protein and α-acid glycoprotein. Bone marrow samples were obtained for the bone marrow iron staining, which was used as the standard for the evaluation of iron status in this study. Subjects were divided into three groups according to hemoglobin levels and bone marrow iron staining results: the IDA (iron deficiency anemia) group, the NIDA (non-iron deficiency anemia) group, and the control group. The differences of the above-mentioned indexes were compared among the three groups and the effect of inflammation was also considered. The cut-off value of reticulocyte hemoglobin content was determined by receiver operation curves. The IDA group (n = 56) had significantly lower reticulocyte hemoglobin content, mean cellular volume, corpuscular hemoglobin concentration, hemoglobin content, and serum ferritin; and higher free erythrocyte protoporphyrin, unsaturated iron-binding capacity, and serum transferrin receptor (p < 0.05) compared with the NIDA group (n = 38) and control group (n = 46). Hematocrit, serum ferritin, and unsaturated iron-binding capacity were significantly affected by inflammation while reticulocyte hemoglobin content and other parameters were not. The cut-off value of reticulocyte hemoglobin content for diagnosing iron deficiency anemia was 27.2 pg, with a sensitivity of 87.5% and a specificity of 92.9%. The cut-off values for mean cellular volume, serum ferritin, and serum transferrin receptor were 76.6, 12.9, and 4.89 mg/L, respectively. Reticulocyte hemoglobin content had the largest area under the curve of 0.929, while those for mean cellular volume, serum ferritin, serum transferrin receptor were 0.922, 0.887, and 0.900, respectively. Reticulocyte hemoglobin content has a high sensitivity and specificity in the diagnosis of iron deficiency anemia, and its comprehensive diagnostic efficacy is better than other traditional indicators—such as serum ferritin and serum transferrin receptor.

1 April 2022 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
DFDongdong Fang
Dongdong Fang
DLDan Li
Dan Li
CLChengjing Li
Chengjing Li
WYWenyu Yang
Wenyu Yang
FXFeng Xiao
Feng Xiao
JGJian Ge
Jian Ge

30 May 2015 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
JHJiansong Huang
Jiansong Huang
XSXiaofeng Shi
Xiaofeng Shi
WXWenda Xi
Wenda Xi
PLPing Liu
Ping Liu
JGJian Ge
Jian Ge
XXXiaodong Xi
Xiaodong Xi
Interaction of integrin β3 with c-Src plays critical roles in cellular signaling which is heavily implicated in platelet adhesion and aggregation, as well as in tumor cell proliferation and metastasis or in osteoclastic bone resorption. Selectively blocking integrin αIIbβ3 outside-in signaling in platelets has been a focus of attention because of its effective antithrombotic potential together with a sufficient hemostatic capacity. The myristoylated RGT peptide has been shown to achieve this blockade by targeting the association of c-Src with the integrin β3 tail, but the lack of key information regarding the mechanisms of action prevents this strategy from being further developed into practical antithrombotics. Therefore, in-depth knowledge of the precise mechanisms for RGT peptide in regulating platelet function is needed to establish the basis for a potential antithrombotic therapy by targeting c-Src. The reduction-sensitive peptides were applied to rule out the membrane anchorage after cytoplasmic delivery. The c-Src activity was assayed at living cell or at protein levels to assess the direct effect of RGT targeting on c-Src. Thrombus formation under flow in the presence of cytoplasmic RGT peptide was observed by perfusing whole blood through the collagen-coated micro-chamber. The RGT peptide did not depend on the membrane anchorage to inhibit outside-in signaling in platelets. The myr-AC ~ CRGT peptide readily blocked agonist-induced c-Src activation by disrupting the Src/β3 association and inhibited the RhoA activation and collagen-induced platelet aggregation in addition to the typical outside-in signaling events. The myr-AC ~ CRGT had no direct effect on the kinase activity of c-Src in living cells as evidenced by its inability to dissociate Csk from c-Src or to alter the phosphorylation level of c-Src Y416 and Y527, consistent results were also from in vitro kinase assays. Under flow conditions, the myr-AC ~ CRGT peptide caused an inhibition of platelet thrombus formation predominantly at high shear rates. These findings provide novel insights into the molecular mechanisms by which the RGT peptide regulates integrin signaling and platelet function and reinforce the potential of the RGT peptide-induced disruption of Src/β3 association as a druggable target that would finally enable in vivo and clinical studies using the structure-based small molecular mimetics.

9 March 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AWAnran Wu
Anran Wu
WZWenjin Zuo
Wenjin Zuo
BGBeibei Gao
Beibei Gao
YCYuyue Cao
Yuyue Cao
HYHongkai Yu
Hongkai Yu
XSXiaofeng Shi
Xiaofeng Shi
Multiple myeloma (MM) is a malignant hematological tumor characterized by the proliferation of monoclonal plasma cells, often accompanied by systemic complications such as bone destruction, renal dysfunction, and hypercoagulability. Plasma D-dimer, as a fibrinolytic marker, may be associated with disease activity. However, there are few reports on the application of plasma D-dimer in evaluating treatment efficacy in MM. This multicenter retrospective study aimed to evaluate the utility of plasma D-dimer levels in predicting treatment response in patients with MM. 160 patients with newly diagnosed MM were enrolled. Blood samples were collected from these patients during their first hospital visit and again after eight cycles of chemotherapy to measure D-dimer levels. This study explores the relationship between plasma D-dimer levels before and after treatment and patient clinical characteristics. Patients showed no statistically different plasma D-dimer levels at initial consultation across treatment-response groups: CR group (0.96 µg/mL [0.67–1.9]), PR group (0.88 µg/mL [0.56–1.39]), SD group (0.68 µg/mL [0.56–0.89]), and PD group (0.91 µg/mL [0.52–1.55]). After chemotherapy, both the absolute change (Dd) and percentage change (Ddp) in D-dimer levels showed significant differences among groups (p < 0.05). The CR and PR groups exhibited significantly greater reductions in D-dimer (Dd: -0.42 and − 0.40 µg/mL; Ddp: -45.2% and − 39.1%) compared to the PD group (Dd: 0.16 µg/mL; Ddp: 18.7%). Patients with overall response (OR) (CR and PR groups) had significantly greater decreases in both Dd and Ddp compared to no-response patients (PD and SD groups) (p < 0.001). Our results suggested that changes in plasma D-dimer levels before and after treatment may provide valuable insights for assessing chemotherapy efficacy in MM.

24 January 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RSRuonan Shao
Ruonan Shao
DMDanchen Meng
Danchen Meng
BGBeibei Gao
Beibei Gao
LZLu Zhang
Lu Zhang
QMQingqi Meng
Qingqi Meng
XSXiaofeng Shi
Xiaofeng Shi
It has been documented that D-dimer levels have potential utility as a measure of tumor activity in diffuse large B-cell lymphoma (DLBCL), however whether it can be used as a predictive marker of treatment outcome has not been established. This study means to retrospectively evaluate the role of D-dimer in prediction of treatment efficacy in patients with DLBCL. 151 patients with newly diagnosed DLBCL were enrolled. Blood samples were taken from those patients during the initial visit to our hospital and again after two cycles of chemotherapy to measure D-dimer levels. The link between plasma D-dimer concentrations and patients’ clinical characteristics was explored before and after treatment. D-dimer levels within the range of 0–1 µg/mL were considered negative, while readings above this range were considered positive. D-dimer difference percentage (Ddp) represents the percentage change in D-dimer levels before and after chemotherapy, calculated as (post-chemotherapy D-dimer minus pre-chemotherapy D-dimer) / pre-chemotherapy D-dimer × 100. Patients showed statistically different plasma D-dimer levels at initial consultation across treatment-response groups: CR (0.63 µg/mL [0.43–1.27]), PR (1.39 µg/mL [0.73–2.46]), SD (0.89 µg/mL [0.59–1.24]), and PD (1.34 µg/mL [0.67–2.62]). After chemotherapy, the PR group exhibited a mean D-dimer level of -0.38 µg/mL (range − 1.64 to -0.11), which was significantly lower than that of the PD group (mean 0.04 µg/mL, range − 0.40 to 0.79; p < 0.05). The CR group revealed significantly lower initial D-dimer levels (median 0.63 µg/mL) and greater reductions after chemotherapy compared to the non-CR group (median 1.17 µg/mL, p < 0.05). Patients with coagulation disorders such as DIC, DVT, or PE were excluded to minimize confounding factors. While this study demonstrates the utility of D-dimer in predicting short-term treatment response, the relationship with long-term outcomes such as PFS and OS requires further investigation. Patients who respond well to chemotherapy typically exhibit lower D-dimer levels at the initial diagnosis. Those in the SD or PD groups usually experience a greater increase in D-dimer levels following chemotherapy. Consequently, variations in plasma D-dimer levels before and after treatment may offer valuable insights for evaluating the efficacy of chemotherapy treatment.